The Glyceraldehyde 3 Phosphate Dehydrogenase pipeline drugs market research report outlays comprehensive information on the Glyceraldehyde 3 Phosphate Dehydrogenase targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses the drugs in the Glyceraldehyde 3 Phosphate Dehydrogenase pipeline by therapy areas, indications, stages, MoA, RoA, molecule type and the key players in the development pipeline. Buy the report here.
Smarter leaders trust GlobalData
The report also covers products from therapy areas such as Oncology, Central Nervous System, and Infectious Disease which include the indications Melanoma, Pancreatic Cancer, Multiple Sclerosis, Gram-Positive Bacterial Infections, and Escherichia coli Infections. It also reviews key players involved in Glyceraldehyde 3 Phosphate Dehydrogenase targeted therapeutics development with respective active and dormant or discontinued products.
The Glyceraldehyde 3 Phosphate Dehydrogenase pipeline targets constitutes close to seven molecules. Out of which, approximately six molecules are developed by companies and the remaining by the universities/institutes. The molecules developed by companies in Phase II, Preclinical, and Discovery stages are 2, 2, and 2 respectively. Similarly, the universities portfolio in Preclinical comprises 1 molecule.
Glyceraldehyde 3 Phosphate Dehydrogenase overview
Glyceraldehyde 3-Phosphate Dehydrogenase is an enzyme that in humans is encoded by a gene GAPDH. This enzyme involved in glycolysis metabolic pathway that converts glucose into energy. In carbohydrate metabolism this enzyme catalyzes an important energy-yielding step that is reversible oxidative phosphorylation of glyceraldehyde-3-phosphate in the presence of inorganic phosphate and nicotinamide adenine dinucleotide (NAD). It has been implicated in various cellular processes, including DNA repair, apoptosis, and the regulation of gene expression. GAPDH has been associated with certain neurodegenerative disorders, it has been found to be involved in processes leading to cell death.
For a complete picture of Glyceraldehyde 3 Phosphate Dehydrogenase’s drug pipeline, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third-party sources.
Drug profiles featured in the report undergo periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
